Emcure Pharmaceuticals - Hindustan Unilever among 5 stocks crossing below VWAP, signalling bearish trend
NiveshIQ
NSE: EMCURE · Pharma
Emcure Pharmaceuticals Ltd.
₹1,903.70▲ ₹11.50 (+0.61%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on EMCURE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Limited is a leading Indian pharmaceutical company providing quality and affordable healthcare solutions worldwide. It operates across various therapeutic areas, including gynecology, anti-infectives, pain/analgesics, and oncology, among others. The company offers its products under several brand names, including Orofer XT, Tenectase, and Vylda. Emcure has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. In FY26, Emcure's revenue rose 16.6% to ₹9,204 crore, with a 33.1% increase in profit after tax. The company has a strong presence in the Indian market and is expected to continue its growth trajectory. Emcure's diversified product portfolio and strategic partnersh
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,658 Cr +11.20% | ₹7,896 Cr +18.60% | ₹9,204 Cr +16.60% |
| EBITDA Margin | 18.47% | 18.67% | 20.30% |
| Net Profit | ₹528.00 Cr -6.00% | ₹708.00 Cr +34.10% | ₹940.74 Cr +32.90% |
| EPS | ₹27.53 | ₹36.32 | ₹48.76 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1,946.90 as Momentum Builds Across Timeframes
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1957.8
🔒
+ 3 more stories about Emcure Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹2, 470 Cr, PAT ₹244 Cr, EPS ₹12.84, EBITDA margin 19.6%. Growth context: revenue YoY +16.7%, PAT YoY +23.7%, revenue QoQ +4.5%, PAT QoQ +5.5%. Street verdict: miss, revenue surprise +0.5%, PAT surprise -4.9%.
Management commentary highlights key growth drivers, including product launches, approvals, and therapy-mix improvement,...
FY26 (last completed FY): revenue ₹9, 204 Cr, PAT ₹941 Cr, EBITDA margin 20.3%, EPS ₹48.76. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for EMCURE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track EMCURE alongside your other holdings
Unlock full EMCURE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Emcure Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Emcure Pharmaceuticals Ltd. (EMCURE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Emcure Pharmaceuticals Ltd.?
Emcure Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹3,120,644.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.